BJDX
Bluejay Diagnostics, Inc.
$4.80
-9.43%
$5.5M
No data for this timeframe.
Vol
Market Cap$5.5M
Cap SizeNano Cap
Insider Activity4B / 0S
Insider Net $$100.0K
Reddit Sentiment69° Warm
SEC Reports4
Press Releases2
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001704287·Prev Close $5.30
Recent Activity
Jun 2, 2026
Press
Bluejay Diagnostics announced a private placement raising $8.5 million upfront (up to $23.6 million with warrant exercis
Impact 5/10
Jun 2, 2026
offering
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
<p align="center"><strong><em>$8.5 million upfront with up to approximately $15.1 million of potenti
Jun 2, 2026
Press
Bluejay Diagnostics entered into a manufacturing services agreement with Argonaut Manufacturing Services to establish U.
Impact 4/10
May 18, 2026
SEC
Two directors collectively purchased $50K worth of BJDX stock at $2.00/share shortly after Q1 2026 earnings (net loss un
CLUSTER — Impact 7/10
May 7, 2026
SEC
Bluejay Diagnostics provided a Q1 2026 corporate update highlighting continued enrollment in its SYMON-II pivotal study
PRESS-RELEASE — Impact 2/10
May 7, 2026
SEC
Bluejay Diagnostics reported Q1 2026 results with cash of $3.7M and a net loss of $1.9M, unchanged YoY. The company prov
8-K — Impact 3/10
Mar 14, 2026
Insider
Dey Indranil bought 12,500 shares
President and CEO @ $2.00 ($25.0K)
Mar 14, 2026
Insider
Wurth Douglas Clark bought 12,500 shares
Director @ $2.00 ($25.0K)
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 3, 2023 | Dawson James | DOWNGRADE | Buy → Neutral |
Latest Reports
BEARISH
Press
5/10
Bluejay Diagnostics announced a private placement raising $8.5 million upfront (up to $23.6 million with warrant exercis
Jun 2, 2026
BULLISH
CLUSTER
7/10
Two directors collectively purchased $50K worth of BJDX stock at $2.00/share shortly after Q1 2026 earnings (net loss un
May 18, 2026
NEUTRAL
PRESS-RELEASE
2/10
Bluejay Diagnostics provided a Q1 2026 corporate update highlighting continued enrollment in its SYMON-II pivotal study
May 7, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 14, 2026 | Dey Indranil | BUY | $25.0K |
| Mar 14, 2026 | Wurth Douglas | BUY | $25.0K |
| Mar 14, 2026 | CHASE DONALD | BUY | $25.0K |
| Mar 14, 2026 | ZEIDMAN FRED | BUY | $25.0K |
Reddit Sentiment
69°
Warm
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
4 unique insiders with 4 transactions. Net insider value: $100.0K ($100.0K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 14, 2026 | Dey Indranil | President and CEO | BUY | 12,500 | $2.00 | $25.0K |
| Mar 14, 2026 | Wurth Douglas Clark | Director | BUY | 12,500 | $2.00 | $25.0K |
| Mar 14, 2026 | CHASE DONALD R | Director | BUY | 12,500 | $2.00 | $25.0K |
| Mar 14, 2026 | ZEIDMAN FRED S | Director | BUY | 12,500 | $2.00 | $25.0K |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.5/10.
BULLISH
CLUSTER
7/10
Two directors collectively purchased $50K worth of BJDX stock at $2.00/share shortly after Q1 2026 e
May 18, 2026
NEUTRAL
PRESS-RELEASE
2/10
Bluejay Diagnostics provided a Q1 2026 corporate update highlighting continued enrollment in its SYM
May 7, 2026
NEUTRAL
8-K
3/10
Bluejay Diagnostics reported Q1 2026 results with cash of $3.7M and a net loss of $1.9M, unchanged Y
May 7, 2026
BULLISH
8-K
6/10
Bluejay Diagnostics announced the enrollment of 624 patients in its pivotal SYMON-II clinical trial
Apr 7, 2026
Historical analyst distribution (last covering-analyst action Aug 2023): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2024-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 3, 2023 | Dawson James | DOWNGRADE | Buy | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jul 1, 2024 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jun 1, 2024 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2024 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2024 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
69°
Warm
Bearish
Neutral
Bullish
4 mentions
3 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 17, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
BJDX: Why I’m Watching This One
▲ 1
💬 0
⚡ 0.5
Why $BJDX Is Exploding Today! 🚀 Hot Stock Gainers
▲ 1
💬 1
⚡ 0.5
$BJDX anyone invested. Micro float. Anyone invested?
▲ 1
💬 1
⚡ 0.0
Jun 2, 2026
offering
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
<p align="center"><strong><em>$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in
Jun 2, 2026
contract
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
<p>ACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) (NASDAQ: BJDX), a med
Jun 2, 2026
short_volume
Short Volume: BJDX — 55.7% short (12.7M / 22.9M)
Short: 12,725,276 | Exempt: 138,578 | TRF Vol: 22,861,811 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
<p>ACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on i
Apr 7, 2026
other
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
<p>ACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on
Mar 12, 2026
routine
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented. <pre>New clinical data from the SY
Mar 6, 2026
other
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
<p>ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- <strong>Bluejay Diagnostics, Inc. (NASDAQ: BJDX)</strong> (“Bluejay” or the “Company”), a medica